Description:

This is a first-in-human, dose escalation and efficacy study of [212Pb]Pb-ADVC001 in participants with PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) who have not had prior exposure to [177Lu]Lu-PSMA based radioligand therapies.